BioCryst Pharmaceuticals BCRX License and other revenues — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's license and other revenues — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's license and other revenues — total revenues?
- BioCryst Pharmaceuticals (BCRX) reported license and other revenues — total revenues of $5.01M in Q1 2026.
- How has BioCryst Pharmaceuticals's license and other revenues — total revenues changed year-over-year?
- BioCryst Pharmaceuticals's license and other revenues — total revenues increased by 186.9% year-over-year, from $1.75M to $5.01M.
- What does license and other revenues — total revenues mean?
- This metric represents the total income recognized from licensing intellectual property, collaborative research agreements, and other non-product sales activities within a specific business segment. It reflects the company's ability to monetize its research and development pipeline through partnerships rather than direct commercial product sales. Monitoring this helps investors assess the success of the company's business development strategy and the value of its proprietary technology portfolio.